GNRH1 and diabetes mellitus: Endocrine therapies, like tamoxifen, aromatase inhibitors, and GnRH agonists, increase diabetes risk potentially by reducing insulin sensitivity and promoting apoptosis in pancreatic β‐cells.31, 56, 57